Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
141.51
-0.35 (-0.25%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 140.29 - 144.07
52 week 110.53 - 174.66
Open 141.98
Vol / Avg. 2.97M/4.47M
Mkt cap 57.46B
P/E 41.97
Div/yield     -
EPS 3.37
Shares 406.02M
Beta 0.97
Inst. own 84%
Jun 18, 2014
Celgene Corp. Annual Shareholder Meeting Add to calendar
Apr 24, 2014
Q1 2014 Celgene Corp. Earnings Release - 9:30AM EDT - Add to calendar
Apr 24, 2014
Q1 2014 Celgene Corp. Earnings Conference Call - 9:00AM EDT - Add to calendar
Mar 12, 2014
Celgene Corp. at Barclays Healthcare Conference
Mar 4, 2014
Celgene Corp. at Cowen Health Care Conference
Feb 26, 2014
Celgene Corp. at RBC Capital Markets Healthcare Conference
Jan 30, 2014
Q4 2013 Celgene Corp. Earnings Release
Jan 30, 2014
Q4 2013 Celgene Corp. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 12.21% 22.33%
Operating margin 18.55% 27.86%
EBITD margin - 36.25%
Return on average assets 6.37% 11.55%
Return on average equity 14.98% 25.70%
Employees 5,100 -
CDP Score - 80 C

Address

86 MORRIS AVENUE
SUMMIT, NJ 07901
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

Officers and directors

Robert J. Hugin Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jacqualyn A. Fouse Ph.D. Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Perry A. Karsen Chief Operations Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Lawrence V. Stein Executive Vice President, General Counsel, Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
Mark J. Alles Executive Vice President, Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Executive Vice President, President - Research and Early Development
Age: 59
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Richard W. Barker OBE Independent Director
Age: 64
Bio & Compensation  - Reuters
Carrie S. Cox Independent Director
Age: 56
Bio & Compensation  - Reuters
Rodman L. Drake Independent Director
Age: 71
Bio & Compensation  - Reuters